Effect of Spleen Amino Peptide Oral Lyophilized Powder in the treatment of childhood asthma with repeated respiratory infections and its influence on inflammatory factors" />
Effect of Spleen Amino Peptide Oral Lyophilized Powder in the treatment of childhood asthma with repeated respiratory infections and its influence on inflammatory factors
Objective To investigate the clinical effect of Spleen Amino Peptide Oral Lyophilized Powder in the treatment of childhood bronchial asthma with recurrent respiratory infection (RRI) and its influence on inflammatory factors and immune function.Methods A total of 74 children with bronchial asthma and RRI who were admitted to Respiratory Department of He′nan Children′s Hospital from June 2018 to October 2019 were selected as the reasearch subjects.They were divided into experimental group and control group by the random number table method, with 37 cases in each group.In the control group, inhaled glucocorticoid (ICS) alone was provided, and in the experimental group,Spleen Amino Peptide Oral Lyophilized Powder was added on the basis of the ICS.The clinical treatment effect, blood immunoglobulin E (IgE) and interleukin 6 (IL-6), interleukin 17 (IL-17) levels and changes in lymphocyte subsets were compared in the two groups.Results The frequency of respiratory infections, the hospital stay, the times of acute asthma attacks, and the use of fast-acting β2 receptor agonist (SABA) in the experimental group were less than those in the control group, the duration of antibiotic use was shorter than that of control group, and the differences were statistically significant (P<0.05).The blood levels of IgE, IL-6 and IL-17 in the experimental group were lower than those before treatment, and lower than those after treatment in the control group, and the differences were statistically significant (P<0.05).The percentages of peripheral blood CD3+, CD4+, CD8+ lymphocytes in the experimental group after treatment were higher than those before treatment, and higher than those after treatment in the control group, the differences were statistically significant (P<0.05).Conclusion The application of ICS combined with Spleen Amino Peptide Oral Lyophilized Powder for bronchial asthma in children with RRI can effectively prevent RRI, minimize the number of acute asthma attacks, and improve asthma control, reduce blood IgE and the levels of inflammatory factors such as IL-6 and IL-17, and enhance immune function.
Effect of Spleen Amino Peptide Oral Lyophilized Powder in the treatment of childhood asthma with repeated respiratory infections and its influence on inflammatory factors
Macias AE,Guaní-Guerra E.Transfer Factor:Myths and Facts[J].Arch Med Res,2020,51(7):613-622.
[9]
Garritano CRO,Nubila FD,Couto RM,et al.Use of transfer factor in immunosuppressed surgical patients[J].Rev Col Bras Cir,2017,44(5):452-456.
[10]
Ayala MC,González NM,Palacios G,et al.Dialyzed leukocyte extracts for the treatment of recurrent and severe infections in pediatric patients with cellular immunodeficiency:15 years of experience[J].Rev Alerg Mex,2019,66(1):27-37.
Qiao J.Influence of spleen aminopeptidase on immune function in the treatment of children with bronchial asthma[J].J Clin Pulmonary Med,2014,19(11):2055-2056.
Jevnikar Z,stling J,Ax E,et al.Epithelial IL-6 trans-signaling defines a new asthma phenotype with increased airway inflammation[J].J Allergy C1in Immunol,2019,143(2):577-590.
[18]
Prenissl N,Lokau J,Rose-John S,et al.Therapeutic blockade of the interleukin-6 receptor(IL-6R)allows sIL-6R generation by proteolytic cleavage[J].Cytokine,2019(2):1-5.
Zou XL,Chen ZG,Zhang TT,et al.Th17/Treg homeostasis,but not Th1/Th2 homeostasis,is implicated in exacerbation of human bronchial asthma[J].Ther Clin Risk Manag,2018,14(8):1627-1636.
[21]
Bullone M,Carriero V,Bertolini F,et al.Elevated Serum IgE,Oral Corticosteroid Dependence and IL-17/22 Expression in Highly Neutrophilic Asthma[J].Eur Respir J,2019,54(5):1900068.
[22]
Li P,Yang QZ,Wang W,et al.Increased IL-4- And IL-17-producing CD8+Cells Are Related to Decreased CD39+CD4+Foxp3+Cells in Allergic Asthma[J].J Asthma,2018,55(1):8-14.